Supplementary Materials for the First Quarter of the Fiscal Year Ending December 2026 Consolidated Financial Results [IFRS] | CHUGAI PHARMACEUTICAL CO.,LTD. (4519) timely disclosure

Worth reading

83Important

Scored from 4 of 6 sections

Direction

Improvement

Direction inferred from the company’s description.

Scale

16.2

Year-on-year change in operating profit (%)

Wording

Conditional

How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportFirst quarter of the fiscal year ending December 20268 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales3,217 Hundreds of millions of yen+11.5%

Operating profit1,588 Hundreds of millions of yen+16.2%

Ordinary income1,602 Hundreds of millions of yen+18.0%

Net income1,154 Hundreds of millions of yen+18.7%

Selling, general and administrative expenses-289 Hundreds of millions of yen

Gross Profit Margin

Rate71.2

Operating profit margin

Rate49.4

Results for the three months of the current quarter

Revenue

3,217 Hundreds of millions of yen+11.5%

Operating profit

1,588 Hundreds of millions of yen+16.2%

Quarterly profit

1,154 Hundreds of millions of yen+18.7%

Core operating profit

1,633 Hundreds of millions of yen+17.1%

Core profit for the quarter

1,186 Hundreds of millions of yen+19.6%

Full-year earnings forecast

Revenue

13,450 Hundreds of millions of yen

Sales of products and merchandise

11,000 Hundreds of millions of yen

Operating profit

6,700 Hundreds of millions of yen

Profit for the period

4,850 Hundreds of millions of yen

Core EPS

¥295

What the company explained in this material

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Reconciliation from IFRS actual results to Core actual results

January–March 2025

Amortization of intangible assets4

Impairment losses on intangible assets1

Business restructuring expenses22

Site reorganization costs1

January–March 2026

Amortization of intangible assets5

Business restructuring expenses40

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

Exchange rate

CHF

Actual results for January–March 2026182.56

2026 full-year forecast184

EUR

Actual results for January–March 2026183.32

2026 full-year forecast179

USD

Actual results for January–March 2026149.85

2026 full-year forecast151

SGD

Actual results for January–March 2026122.22

2026 full-year forecast119

New initiatives

RG7828 progressed from filing to approval for relapsed or refractory large B-cell lymphoma
Initiation of Phase 3 development of RG6114 for PIK3CA mutation-positive, HER2-positive breast cancer
Initiation of Phase 3 development of RG6114 for PIK3CA mutation-positive breast cancer
Discontinuation of development of RG7446 as second-line treatment for hepatocellular carcinoma
Discontinuation of development of GYM329/RG6237 for SMA and FSHD
Discontinuation of development of Enspryng for DMD

Key KPIsA metric the company considers important as a management benchmark.

Core EPS¥72.03
Year on year against the same period last year+19.5%
Operating free cash flow2,033 Hundreds of millions of yen
Free cash flow1,122 Hundreds of millions of yen
Core ROIC10.8 %
ROE5.9 %
PBR7.4 times
CCC9.9 Month

Number of employees

Number of Employees7,805 people

Capital expenditures

¥97 100 million investment in property, plant and equipment, January–March 2026

Annual Dividend

Annual dividend per share¥132

Interim¥66

End of period¥66

Payout ratio

Rate44.7 %

Contents of this document
Item	Details
Document type	Supplementary materials to the earnings report
Fiscal Period Covered	First quarter of the fiscal year ending December 2026
Net Sales	3,217 Hundreds of millions of yen (YoY +11.5%)
Operating profit	1,588 Hundreds of millions of yen (YoY +16.2%)
Ordinary income	1,602 Hundreds of millions of yen (YoY +18.0%)
Net income	1,154 Hundreds of millions of yen (YoY +18.7%)
Gross Profit Margin	Rate 71.2 / Year-on-year change (points) Not disclosed
Operating profit margin	Rate 49.4 / Year-on-year change (points) Not disclosed
Selling, general and administrative expenses	-289 Hundreds of millions of yen
Results for the three months of the current quarter	Revenue 3,217 Hundreds of millions of yen (YoY +11.5%) / Operating profit 1,588 Hundreds of millions of yen (YoY +16.2%) / Quarterly profit 1,154 Hundreds of millions of yen (YoY +18.7%) / Core operating profit 1,633 Hundreds of millions of yen (YoY +17.1%) / Core profit for the quarter 1,186 Hundreds of millions of yen (YoY +19.6%)
Full-year earnings forecast	Revenue 13,450 Hundreds of millions of yen / Sales of products and merchandise 11,000 Hundreds of millions of yen / Operating profit 6,700 Hundreds of millions of yen / Profit for the period 4,850 Hundreds of millions of yen / Core EPS ¥295
Breakdown of Factors Affecting the Change	Reconciliation from IFRS actual results to Core actual results January–March 2025 Amortization of intangible assets 4 / Impairment losses on intangible assets 1 / Business restructuring expenses 22 / Site reorganization costs 1 / January–March 2026 Amortization of intangible assets 5 / Business restructuring expenses 40
Key KPIs	Indicator name Core EPS / Value ¥72.03 / Year on year against the same period last year ¥19.5, Indicator name Operating free cash flow / Value 2,033 Hundreds of millions of yen / Year on year against the same period last year Not disclosed, Indicator name Free cash flow / Value 1,122 Hundreds of millions of yen / Year on year against the same period last year Not disclosed, Indicator name Core ROIC / Value 10.8 % / Year on year against the same period last year Not disclosed, Indicator name ROE / Value 5.9 % / Year on year against the same period last year Not disclosed, Indicator name PBR / Value 7.4 times / Year on year against the same period last year Not disclosed, Indicator name CCC / Value 9.9 Month / Year on year against the same period last year Not disclosed
Number of employees	Number of Employees 7,805 people / Changes during the period and hiring plan Not disclosed
Assumptions Underlying the Business Outlook	Exchange rate CHF Actual results for January–March 2026 182.56 / 2026 full-year forecast 184 / EUR Actual results for January–March 2026 183.32 / 2026 full-year forecast 179 / USD Actual results for January–March 2026 149.85 / 2026 full-year forecast 151 / SGD Actual results for January–March 2026 122.22 / 2026 full-year forecast 119
Annual Dividend	Annual dividend per share ¥132 / Interim ¥66 / End of period ¥66
Payout ratio	Rate 44.7 %
Capital expenditures	¥97 100 million (investment in property, plant and equipment, January–March 2026)
New initiatives	RG7828 progressed from filing to approval for relapsed or refractory large B-cell lymphoma, Initiation of Phase 3 development of RG6114 for PIK3CA mutation-positive, HER2-positive breast cancer, Initiation of Phase 3 development of RG6114 for PIK3CA mutation-positive breast cancer, Discontinuation of development of RG7446 as second-line treatment for hepatocellular carcinoma, Discontinuation of development of GYM329/RG6237 for SMA and FSHD, Discontinuation of development of Enspryng for DMD

Items this document does not state (12)

Progress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The document does not explain the reasons for changes in performance. It does provide results by product and region, including a 14.9% year-on-year increase in overseas sales of products, a 26.3% increase in overseas sales of Hemlibra, and a 7.1% decrease in overseas sales of Actemra.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.